Picking Up The Pieces Of “Cures”: Senate Process Resets Focus On 2017
This article was originally published in RPM Report
Executive Summary
The Senate Health Committee is planning a series of legislative mark-ups for 2016 billed as the companion process to the House “21st Century Cures” process. The real message is that Cures won’t move in 2016 – but the work should carry over to the user fee process in 2017.
You may also be interested in...
Priority Review Vouchers: Buyers Beware!
The recent series of sales of priority review vouchers at ever-higher prices has transformed what had seemed to be a failed incentive model into a hot topic. However, one key stakeholder is not celebrating the recent developments: the FDA review teams that have to deliver the faster paced reviews continue to have strong reservations about the program.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.